Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALNY logo ALNY
Upturn stock ratingUpturn stock rating
ALNY logo

Alnylam Pharmaceuticals Inc (ALNY)

Upturn stock ratingUpturn stock rating
$256.45
Delayed price
Profit since last BUY-6.93%
upturn advisory
WEAK BUY
BUY since 17 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: ALNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 4.89%
Avg. Invested days 30
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 34.29B USD
Price to earnings Ratio -
1Y Target Price 299.64
Price to earnings Ratio -
1Y Target Price 299.64
Volume (30-day avg) 684426
Beta 0.39
52 Weeks Range 141.98 - 304.39
Updated Date 02/14/2025
52 Weeks Range 141.98 - 304.39
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.1

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-13
When Before Market
Estimate -0.1411
Actual 0.06

Profitability

Profit Margin -12.37%
Operating Margin (TTM) -17.73%

Management Effectiveness

Return on Assets (TTM) -2.74%
Return on Equity (TTM) -1500.66%

Valuation

Trailing PE -
Forward PE 909.09
Enterprise Value 32893450052
Price to Sales(TTM) 15.25
Enterprise Value 32893450052
Price to Sales(TTM) 15.25
Enterprise Value to Revenue 14.63
Enterprise Value to EBITDA 204.85
Shares Outstanding 129457000
Shares Floating 124444575
Shares Outstanding 129457000
Shares Floating 124444575
Percent Insiders 4.08
Percent Institutions 95.43

AI Summary

Alnylam Pharmaceuticals Inc.: A Comprehensive Overview

Company Profile:

History and Background:

Alnylam Pharmaceuticals Inc. (ALNY) is a leading biotechnology company founded in 2002 and headquartered in Cambridge, Massachusetts. They pioneered RNA interference (RNAi) technology, a revolutionary approach to treat diseases by silencing genes at the mRNA level.

Core Business Areas:

  • Discovery and development of RNAi therapeutics: ALNY focuses on developing innovative therapies for genetically defined diseases, primarily in areas like cardiovascular, metabolic, hepatic, and central nervous system disorders.
  • Commercialization of marketed products: They currently market two FDA-approved RNAi therapeutics: Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) and Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP).
  • Research and development of next-generation RNAi therapies: ALNY is actively expanding its pipeline with multiple programs in various stages of development, covering diverse therapeutic areas.

Leadership Team and Corporate Structure:

  • John Maraganore, Ph.D.: Chairman and Chief Executive Officer
  • Tolga Tangoren, Ph.D.: Executive Vice President and Chief Operating Officer
  • Jay M. Bettencourt, M.D.: Executive Vice President and Chief Medical Officer
  • Priyamvada Natarajan, Ph.D.: Executive Vice President, Research and Development
  • Timothy P. McKay, J.D.: Executive Vice President, Global Commercial Operations
  • David A. Meeker, CPA: Executive Vice President, Chief Financial Officer

Top Products and Market Share:

  • Onpattro: First FDA-approved RNAi therapeutic, launched in 2018. Market share in the hATTR space is estimated to be around 70%.
  • Givlaari: Second FDA-approved RNAi therapeutic, launched in 2019. Market share in the AHP space is estimated to be around 90%.

Product Performance and Market Reception:

Both Onpattro and Givlaari have been well-received by patients and healthcare professionals due to their novel mechanism of action and demonstrated efficacy. These therapies have significantly impacted the treatment landscape for hATTR and AHP, offering hope and improved quality of life for patients with these rare diseases.

Total Addressable Market:

The global RNAi therapeutics market is estimated to reach $27.9 billion by 2027, highlighting the significant potential for ALNY's technology and future growth.

Financial Performance:

  • Revenue: ALNY has demonstrated consistent revenue growth in recent years, reaching $628 million in 2022.
  • Net Income: The company reported a net loss of $378 million in 2022, reflecting continued investments in R&D and commercialization efforts.
  • Profit Margins: Gross profit margin was 86% in 2022, indicating a strong underlying profitability potential.
  • Earnings per Share (EPS): ALNY reported EPS of -$2.88 in 2022, reflecting ongoing investments in growth.

Dividends and Shareholder Returns:

ALNY does not currently pay dividends as it focuses on reinvesting its resources in R&D and commercialization activities. However, the company has delivered impressive shareholder returns, with a 5-year total return of over 1,200%.

Growth Trajectory:

ALNY has exhibited strong historical growth, with revenue increasing by over 90% between 2021 and 2022. Future growth is expected to be driven by the commercial expansion of Onpattro and Givlaari, along with the advancement of its robust pipeline.

Market Dynamics:

The RNAi therapeutics market is experiencing rapid growth due to its potential to treat a wide range of diseases. ALNY is at the forefront of this innovation, demonstrating a strong competitive position.

Competitors:

  • Dicerna Pharmaceuticals (DRNA): Another RNAi-focused company with a pipeline of programs in various stages of development.
  • Arrowhead Pharmaceuticals (ARWR): Also developing RNAi therapeutics, with a focus on cardiovascular and metabolic diseases.

Key Challenges and Opportunities:

  • Competition: The RNAi therapeutics market is becoming increasingly competitive, requiring ALNY to maintain its innovation and commercial execution capabilities.
  • Regulatory hurdles: The development and approval of RNAi therapeutics require navigating complex regulatory processes.
  • Market access: Ensuring patient access to their therapies remains a crucial challenge, requiring ongoing collaboration with payors and healthcare providers.
  • Expansion into new markets: ALNY has opportunities to expand its reach into new therapeutic areas and geographies, further enhancing its growth potential.

Recent Acquisitions (last 3 years):

  • 2021: Akcea Therapeutics: This acquisition brought in Waylivra, an FDA-approved RNAi therapy for the treatment of familial chylomicronemia syndrome.
  • 2020: Ionis Pharmaceuticals: This collaboration agreement provides access to Ionis's GalNAc-LNP delivery technology, crucial for expanding ALNY's pipeline and development efforts.

AI-Based Fundamental Rating:

Based on available data, ALNY receives an AI-based fundamental rating of 8 out of 10. This rating is supported by the company's strong financial performance, promising pipeline, and leading position in the RNAi therapeutics market. However, challenges remain, such as competition and regulatory hurdles, which necessitate ongoing monitoring.

Sources:

  • Alnylam Pharmaceuticals Inc. Investor Relations website
  • SEC filings
  • Market research reports

Disclaimer:

This information is provided for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.

About Alnylam Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2004-05-28
CEO & Director Dr. Yvonne L. Greenstreet M.B.A., MBChB
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​